

COVID-19 vaccine updates

Dr. Manish Sadarangani

Associate Professor, Division of Infectious Diseases, Department of Pediatrics, UBC Director, Vaccine Evaluation Center, BC Children's Hospital Research Institute Physician Lead, Family Immunization Clinic, BC Children's Hospital

UBC

25 October 2022





COVID-19 Boosters: BC guidelines (as of 24th October)

Fall 2022 Booster Dose C, D, E		
Eligibility Criteria	Number of Doses	
Individuals 5-11 years of age	1 dose – at least 6 months after the primary series: Pfizer (monovalent): 0.2 mL (10 mcg)	
Individuals 12-17 years of age ^F	 1 dose – at least 6 months after the primary series or a previous booster dose: Pfizer Bivalent: 0.3 mL (30 mcg) Moderna Bivalent: 0.5 mL (50 mcg) – recommended and preferred only for those who are moderately to severely immunosuppressed (see <u>Appendix A</u>) 	
Individuals 18 years of age and older ^F	 1 dose – at least 6 months after the primary series or a previous booster dose: Pfizer Bivalent: 0.3 mL (30 mcg) Moderna Bivalent: 0.5 mL (50 mcg) - preferred for those who are moderately to severely immunosuppressed (see <u>Appendix A</u>) 	




COVID-19 Boosters: BC guidelines (published 7th October)

- 1. NACI strongly recommends that all individuals ≥65 years of age and also individuals ≥12 years of age* <u>who</u> <u>are at increased risk of severe illness from COVID-19</u>** should be offered a fall COVID-19 vaccine booster dose regardless of the number of booster doses previously received. (Strong NACI recommendation)
- 2. NACI recommends that all other individuals 12 to 64 years of age may be offered a fall COVID-19 vaccine booster dose regardless of the number of booster doses previously received. (Discretionary NACI recommendation)
- 3. NACI recommends that bivalent Omicron-containing mRNA COVID-19 vaccines are the preferred booster products for the authorized age groups. (Strong NACI recommendation)
- Moderna Spikevax bivalent BA.1 (50 mcg)
- Pfizer-BioNTech Comirnaty bivalent BA.4/5 (30 mcg)




Moderna Spikevax BA.1 (50 mcg)

- 25 mcg ancestral strain SARS-CoV-2 + 25 mcg Omicron BA.1
- Phase 2-3 trial
 - N=819
 - Primary series: 2 doses of Moderna Spikevax
 - Booster with 50 mcg bivalent *vs.* ancestral strain ≥3 months after dose 2



Solicited Local and Systemic Adverse Reactions




Pfizer Comirnaty BA.4/5 (30 mcg)

- 15 mcg ancestral strain SARS-CoV-2 + 15 mcg Omicron BA.4/5
- No clinical data for BA.4/5
 - Clinical data for BA.1 + preclinical data for BA.4/5

	C4591031 Substudy E ^a (>55y)		
	BNT162b2 30 μg	Bivalent OMI BA.1 30 μg	
	Dose 4 (N=298)	Dose 4 (N=301)	
Local reaction at injection site			
Pain	60.1%	58.1%	
Swelling	6.0%	6.6%	
Redness	6.4%	7.0%	
Systemic events			
Fatigue	45.3%	49.2%	
Headache	26.5%	33.6%	
Muscle pain	19.8%	22.3%	
Chills	16.4%	13.0%	
Joint pain	9.1%	11.3%	
Fever (≥38.0°C)	3.7%	5.0%	
Vomiting	1.3%	1.7%	
Diarrhea	4.4%	9.0%	

a. BNT162b2-experienced participants (>55 years of age) who received BNT162b2 30 µg or BNT162b2 + BNT162b2 OMI BA.1 30 µg as a booster dose (Dose 4) approximately 5 to 12 months after their last dose (Dose 3).



https://www.cdc.gov/vaccines/acip/meetings/downlo ads/slides-2022-09-01/07-covid-swanson-508.pdf

